Neuroleptic malignant syndrome (NMS) is rare but one of the most serious adverse effects of antipsychotics. Here, we report a case of risperidone-associated NMS in which a successful rechallenge of risperidone was observed with a positive follow-up. A 47-year-old female with schizophrenia was treated with risperidone 4 mg/d for 8 months in 2009 and was admitted to our hospital in 2015 owing to violent behavior under persecutory delusions. Risperidone 2 mg/d was initiated and increased to 4 mg/d 54 days later. Further, long-acting injectable (LAI) risperidone 25 mg per 2 weeks was added on hospital day 15. On hospital day 116, NMS occurred and thus we discontinued all antipsychotics including LAI risperidone, then NMS improved. We resumed LAI risperidone 25 mg per 2 weeks on hospital day 148, thus we waited for 22 days before re-starting the drug treatment. She was discharged on hospital day 371, then switched to LAI paliperidone 150 mg per 4 weeks 2 months later. At the time of a follow-up 3 years later, NMS had not reoccurred. This case reports on an unusual presentation of NMS in which no hyperthermia was observed. Furthermore, this case indicated that NMS may occur in a dose-dependent manner. In conclusion, this case reported important information for clinicians with regard to antipsychotic drug rechallenges and proper dosing of APs to avoid or reverse NMS.
Keywords: antipsychotics; hyperthermia; neuroleptic malignant syndrome; risperidone; schizophrenia.
[Case report: Neuroleptic malignant syndrome and diagnostic difficulties].Encephale. 2016 Jun;42(3):277-80. doi: 10.1016/j.encep.2016.01.001. Epub 2016 Feb 26. Encephale. 2016. PMID: 26923996 French.
[A study of neuroleptic malignant syndrome in the presenium and senium].Seishin Shinkeigaku Zasshi. 1998;100(6):387-97. Seishin Shinkeigaku Zasshi. 1998. PMID: 9745353 Japanese.
Neuroleptic malignant syndrome during a change from haloperidol to risperidone.Ann Pharmacother. 2001 Jun;35(6):698-701. doi: 10.1345/aph.10137. Ann Pharmacother. 2001. PMID: 11408988
Risperidone-induced neuroleptic malignant syndrome: a case report and review.Can J Psychiatry. 1996 Feb;41(1):52-4. doi: 10.1177/070674379604100112. Can J Psychiatry. 1996. PMID: 8919425 Review.
[Neuroleptic malignant syndrome and atypical antipsychotics: a brief review].Encephale. 2008 Dec;34(6):618-24. doi: 10.1016/j.encep.2007.11.007. Epub 2008 Apr 2. Encephale. 2008. PMID: 19081460 Review. French.